| MYOK - MyoKardia Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2021-05-31 (Delayed quote data ) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy?hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company?s products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |